Neurogene Inc.

Nasdaq:NGNE

Pharmaceutical Preparations·NEW YORK, NY

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Neurogene Inc.

Nasdaq:NGNE

Pharmaceutical Preparations·NEW YORK, NY

CEO

Mcminn Rachel

CFO

Cvijic Christine Mikail

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$0

-100.0% YoY

FY 2024

Adj. EBITDA

-$52.3M

FY 2024

Net Income

-$36.3M

FY 2024

EPS (Diluted)

$2.93

FY 2024

Stock Price

$23.06

-2.1%

2026-03-10

52W Range

$6.88 – $37.27

P/E Ratio

7.9x

Market Cap

$357.2M

Cash

$148.2M

FY 2024

Total Debt

—

Net Cash

$148.2M

FY 2024

Enterprise Value

$209.0M

Debt / EBITDA

2.8x

FY 2024

EV / EBITDA

-4.0x

Employees

—

CEO

Mcminn Rachel

CFO

Cvijic Christine Mikail

Revenue

$0

-100.0% YoY

FY 2024

Adj. EBITDA

-$52.3M

FY 2024

Net Income

-$36.3M

FY 2024

EPS (Diluted)

$2.93

FY 2024

Stock Price

$23.06

-2.1%

2026-03-10

52W Range

$6.88 – $37.27

P/E Ratio

7.9x

Market Cap

$357.2M

Cash

$148.2M

FY 2024

Total Debt

—

Net Cash

$148.2M

FY 2024

Enterprise Value

$209.0M

Debt / EBITDA

2.8x

FY 2024

EV / EBITDA

-4.0x

Employees

—